In a move set to reshape the landscape of oral drug delivery, AustinPx—a Texas-based contract development and manufacturing organization (CDMO)—has announced an exclusive agreement with the Patheon division of Thermo Fisher Scientific. This collaboration marks a significant milestone in the adoption of KinetiSol technology, a high-performance, solvent-free amorphous solid dispersion (ASD) platform designed to tackle the industry’s most stubborn solubility challenges.
By integrating KinetiSol technology into Thermo Fisher’s established global footprint in Bend, Oregon, and Cincinnati, Ohio, the partnership aims to provide pharmaceutical sponsors with a streamlined, scalable, and risk-mitigated pathway from early-phase development to full-scale commercial manufacturing.
The Challenge of Solubility in Modern Drug Development
The pharmaceutical industry currently faces a "solubility crisis." According to data published in the journal Life in 2023, approximately 40% of all commercialized drugs and an overwhelming 70% to 90% of candidates in the research pipeline are classified as poorly soluble.
Poor aqueous solubility is more than a chemical hurdle; it is a clinical bottleneck. When a drug is poorly absorbed by the body, its bioavailability is compromised, often leading to reduced therapeutic efficacy. To compensate, developers are frequently forced to escalate dosages, which inadvertently increases the risk of systemic side effects and patient non-compliance. For decades, spray drying and hot-melt extrusion (HME) have served as the industry standards for amorphous solid dispersion. However, these methods are not universal solutions. They often hit physical limits regarding thermal stability, solvent compatibility, and the ability to process complex, multi-component drug formulations.
A New Chapter for KinetiSol Technology
KinetiSol, a proprietary technology owned and refined by AustinPx, functions as a high-energy, fusion-based manufacturing process. Unlike traditional methods, it operates without the need for large quantities of volatile solvents or excessive, sustained thermal stress. By providing a "fusion" environment that can handle molecules previously deemed "undruggable," KinetiSol offers a robust alternative to conventional ASD routes.
The agreement with Thermo Fisher is not merely a licensing deal; it is a strategic infrastructure expansion. By placing KinetiSol technology within Thermo Fisher’s Patheon network, AustinPx is effectively plugging its technology into one of the world’s largest and most sophisticated CDMO ecosystems. The integration will also interface with Patheon’s "Quadrant 2" platform, an AI/ML-driven toolset that predicts optimal formulations based on existing data sets, further accelerating the timeline from lead optimization to clinical trial supply.
Chronology of an Evolving Partnership
The journey to this partnership reflects the maturation of KinetiSol from a niche, high-performance tool to a standardized industry solution:
- The Development Phase (Pre-2022): AustinPx spent over 16 years refining the KinetiSol process, building a robust intellectual property portfolio and deep process knowledge through the support of more than 80 client programs.
- The Validation Phase (2022–2025): As the demand for complex molecules grew, AustinPx successfully managed multiple technology transfers and commercial-scale equipment installations, proving the technology’s reliability for registration-scale manufacturing.
- The Strategic Shift (June 2026): AustinPx and Thermo Fisher Scientific announce a formal, exclusive agreement. This deal designates Thermo Fisher as the exclusive third-party CDMO for KinetiSol Formulator services, effectively granting pharmaceutical sponsors a reliable, "safe-harbor" route for late-stage development.
- The Future Outlook (Mid-2026 and beyond): With the technology now embedded in major CDMO sites, the industry expects a surge in the adoption of KinetiSol, as sponsors feel more confident integrating it into their Phase 3 and commercial launch strategies.
Strategic Implications: Why Externalize?
A common question among industry analysts is why AustinPx would choose to route commercial-scale access through an external CDMO rather than vertically integrating that capacity in-house.
According to AustinPx CEO Elizabeth Hickman, the decision is rooted in "commercial optionality."
"We remain the inventor, technology owner, and process experts for KinetiSol," Hickman explains. "Our goal is to give sponsors commercial confidence. When a sponsor moves into Phase 3, they are looking for stability, geographic redundancy, and the capacity of a global giant. By partnering with Thermo Fisher, we aren’t losing our role; we are broadening the ecosystem. We provide the expertise, and Thermo Fisher provides the massive, validated infrastructure that sponsors demand for late-stage clinical and commercial programs."
This move effectively lowers the "barrier to entry" for KinetiSol. Historically, sponsors were hesitant to use "specialized" technologies because they feared a lack of manufacturing redundancy. By creating a standardized path through a global powerhouse like Thermo Fisher, AustinPx has effectively transformed KinetiSol from a "last-resort" option into a primary, high-confidence strategy.
Technical Superiority and the Decision Matrix
For formulation scientists, the selection of an ASD route is a complex decision tree. Hickman notes that the most important factor is the molecule’s chemical nature.
"Spray drying is limited by solvent solubility, and hot-melt extrusion is constrained by thermal sensitivity," Hickman states. "KinetiSol thrives in the gaps between those two."
The specific technical signals that favor KinetiSol include:
- Thermal Sensitivity: Molecules that degrade under the long-duration heat exposure required by standard extrusion.
- Solvent Incompatibility: Compounds that do not dissolve easily in the organic solvents required for spray drying.
- Complex Multi-component Systems: Formulations that require specific polymers or excipients that are incompatible with traditional liquid-phase or melt-phase processes.
- Sustainability Goals: KinetiSol’s solvent-free process aligns with modern ESG mandates to reduce solvent waste in pharmaceutical manufacturing.
The Role of AI in Predictive Formulation
The integration with Thermo Fisher’s "Quadrant 2" platform is perhaps the most forward-looking aspect of the deal. By feeding KinetiSol process and formulation data into an AI/ML-driven prediction engine, the partners are creating a virtuous cycle of learning.
"Predictive tools are only as good as the data you feed them," Hickman notes. "As we incorporate KinetiSol into these broader workflows, we allow the AI to ‘learn’ the behavior of molecules in a fusion-based environment. Over time, this helps our clients avoid low-value experiments and identify the right formulation path much earlier, conserving limited API and reducing the risk of failure in the clinic."
Implications for the Pharmaceutical Industry
The impact of this alliance is twofold. First, it validates the maturity of KinetiSol as a commercial-grade technology. Second, it shifts the competitive dynamics of the CDMO market.
For the average pharmaceutical sponsor, this partnership provides a clear, de-risked roadmap. Sponsors no longer have to choose between a cutting-edge, high-performance technology and a large, established manufacturing partner. They can now access both.
As the industry moves toward more complex, targeted, and harder-to-deliver molecules, the ability to solve for solubility at the earliest stage of development will become a primary competitive advantage. By aligning its technological expertise with the commercial scale of Thermo Fisher, AustinPx has positioned itself—and its partners—at the forefront of this evolution.
Looking ahead, the success of this collaboration will likely be measured by the speed and confidence with which new, poorly soluble drug candidates move through the development pipeline and into the hands of patients, signaling a shift toward more efficient, data-driven, and highly effective drug delivery strategies.
About the Author
